Home > Resources > Whitepapers > Clinical Development: Rare Disease

Clinical Development: Rare Disease

July 19, 2016

According to Global Genes, more than 350 million people worldwide suffer from rare diseases. Unfortunately, according to the FDA’s Every Life Foundation, only around 5% of rare diseases have a FDA-approved treatment. Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, has worked on more than 230 rare disease studies since 2010. Here, Laurie Witherwax outlines the patient-centric approach that Quintiles deploys to help pharmaceutical and biotechnology companies get new therapies to patients.

Spotlight

RCCH HealthCare Partners

Based in Brentwood, Tennessee, RCCH HealthCare Partners is made up of 17 regional health systems located in 13 states. We have more than 14,000 employees and 2,000 affiliated physicians and mid-level providers.

OTHER WHITEPAPERS

The Evidence Base for Telehealth

whitePaper | February 18, 2023

In a very short time, healthcare in the United States and in many other countries has been transformed out of necessity to respond to the COVID-19 pandemic.

The importance for healthcare organizations to extend theprinciples of zero trust to business-critical applications

whitePaper | May 15, 2022

The zero trust security framework is predicated on the foundational concept that implicit trust of users and devices in the environment increases the risk of a potential compromise. By eliminating this implicit trust and requiring strict identification and authentication throughout the network

Three Challenges Facing Study Start Up and the Low-Code Automation Solution

whitePaper | November 24, 2022

The life sciences industry has been exploring ways to accelerate the study start up process for well over a decade. The industry has long understood the value behind faster clinical trials: the sooner clinical trial results can be delivered to agencies

The Rise of Hybrid Clinical Trials

whitePaper | September 21, 2022

Prior to 2020, the answer was likely not very much. Although decentralized trials (DCT) existed prior to the pandemic, COVID-19 undoubtedly had a large impact on the rapid adoption of DCT technologies.

Charting a Course to Sustainable Healthcare and Finance in the Asia-Pacific

whitePaper | October 12, 2021

This report provides solutions to help establish a sustainable healthcare system design in the region and delves into the care pathways for thelife-course immunity strength and well- being, physically, mentally and financially.

Electronic Medical Records (EMR) Software: 2020 Pricing Guide

whitePaper | February 4, 2020

When it comes to electronic medical records (EMR) software, it’s important to find the system best fit for your businesses’ needs, goals, and budget. This guide written by Software Advice, covers everything you need to know about software pricing in 2020. Compare pricing models, price ranges, popular system prices, and unexpected costs of EMR software. In addition to your download, you’ll be able to chat with an advisor in your industry and get personalized software recommendations.

Clinical Development: Rare Disease